| P50 | author | Chiara Cassani | Q85328415 |
| | Simone Ferrero | Q47282621 |
| | Arsenio Spinillo | Q59159199 |
| P2093 | author name string | Pier Luigi Venturini | |
| | Anna Daniela Iacobone | |
| | Barbara Gardella | |
| | Mattia Dominoni | |
| | Stefano Bogliolo | |
| | Anna Orlandini | |
| | Franco Viazzo | |
| P2860 | cites work | Hormonal therapy in advanced or recurrent endometrial cancer | Q24235543 |
| | The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53 | Q24317677 |
| | Characterization of NEDD8, a developmentally down-regulated ubiquitin-like protein | Q24322977 |
| | Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer | Q33423263 |
| | CSN5/Jab1 is involved in ligand-dependent degradation of estrogen receptor {alpha} by the proteasome | Q33837034 |
| | Effects of short-term antiestrogen treatment of primary breast cancer on estrogen receptor mRNA and protein expression and on estrogen-regulated genes | Q59289308 |
| | Importance of the regulation of nuclear receptor degradation | Q34327269 |
| | Fulvestrant: a review of its use in the management of hormone receptor-positive metastatic breast cancer in postmenopausal women | Q34626963 |
| | The turnover of estrogen receptor α by the selective estrogen receptor degrader (SERD) fulvestrant is a saturable process that is not required for antagonist efficacy | Q35027844 |
| | Phase II study of everolimus and letrozole in patients with recurrent endometrial carcinoma | Q35144264 |
| | C terminus of Hsc70-interacting protein (CHIP)-mediated degradation of hippocampal estrogen receptor-alpha and the critical period hypothesis of estrogen neuroprotection | Q35198156 |
| | Combined histone deacetylase inhibition and tamoxifen induces apoptosis in tamoxifen-resistant breast cancer models, by reversing Bcl-2 overexpression | Q35201384 |
| | Estrogen receptor alpha is a putative substrate for the BRCA1 ubiquitin ligase | Q35749504 |
| | Fulvestrant: an oestrogen receptor antagonist with a novel mechanism of action | Q35750078 |
| | Fulvestrant: pharmacokinetics and pharmacology | Q35750083 |
| | Advances in the treatment of endometrial cancer | Q36090826 |
| | Pharmacokinetics, pharmacological and anti-tumour effects of the specific anti-oestrogen ICI 182780 in women with advanced breast cancer | Q36135542 |
| | ERα phosphorylation at Y537 by Src triggers E6-AP-ERα binding, ERα ubiquitylation, promoter occupancy, and target gene expression. | Q36210983 |
| | Fulvestrant: pharmacologic profile versus existing endocrine agents for the treatment of breast cancer | Q36567154 |
| | Molecular and pathologic aspects of endometrial carcinogenesis | Q36617660 |
| | A phase I trial to assess the pharmacology of the new oestrogen receptor antagonist fulvestrant on the endometrium in healthy postmenopausal volunteers | Q36646485 |
| | Aromatase inhibitors in gynecologic cancers | Q36934736 |
| | Proteasome-dependent degradation of the human estrogen receptor | Q37160826 |
| | OTU Domain-containing ubiquitin aldehyde-binding protein 1 (OTUB1) deubiquitinates estrogen receptor (ER) alpha and affects ERalpha transcriptional activity | Q37269111 |
| | G protein-coupled estrogen receptor-selective ligands modulate endometrial tumor growth | Q37393019 |
| | Phase II study of fulvestrant in recurrent/metastatic endometrial carcinoma: a Gynecologic Oncology Group study | Q37809370 |
| | Deubiquitinases and the new therapeutic opportunities offered to cancer | Q38326071 |
| | Effectiveness of aromatase inhibitors in the treatment of advanced endometrial adenocarcinoma | Q38670417 |
| | Gene expression profiling in Ishikawa cells: a fingerprint for estrogen active compounds | Q39860227 |
| | Definition of functionally important mechanistic differences among selective estrogen receptor down-regulators | Q40073529 |
| | Differential regulation of estrogen receptor alpha turnover and transactivation by Mdm2 and stress-inducing agents | Q40124566 |
| | An inhibitory effect on cell proliferation by blockage of the MAPK/estrogen receptor/MDM2 signal pathway in gynecologic cancer | Q40170177 |
| | The effects of estradiol and selective estrogen receptor modulators on gene expression and messenger RNA stability in immortalized sheep endometrial stromal cells and human endometrial adenocarcinoma cells | Q40649825 |
| | Proteasome-mediated proteolysis of estrogen receptor: a novel component in autologous down-regulation | Q40930380 |
| | Structural components necessary for the antiestrogenic activity of tamoxifen | Q41288701 |
| | Circumvention of tamoxifen resistance by the pure anti-estrogen ICI 182,780. | Q41514542 |
| | The paracrine stimulation of MCF-7 cells by MDA-MB-231 cells: possible role in antiestrogen failure | Q41959489 |
| | FDA drug approval summaries: fulvestrant | Q42691178 |
| | Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer. | Q42882393 |
| | Phase II study of fulvestrant 250 mg/month in patients with recurrent or metastatic endometrial cancer: a study of the Arbeitsgemeinschaft Gynäkologische Onkologie | Q44208606 |
| | The NEDD8 pathway is required for proteasome-mediated degradation of human estrogen receptor (ER)-alpha and essential for the antiproliferative activity of ICI 182,780 in ERalpha-positive breast cancer cells | Q44294730 |
| | Pharmacokinetic profile of intramuscular fulvestrant in advanced breast cancer | Q44915900 |
| | Fulvestrant (ICI 182,780)-dependent interacting proteins mediate immobilization and degradation of estrogen receptor-alpha | Q46928900 |
| | Treating gynecologic malignancies with selective estrogen receptor downregulators (SERDs): promise and challenges. | Q55049851 |
| | Endometrial cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up | Q56019470 |
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 537-544 | |
| P577 | publication date | 2016-10-04 | |
| P1433 | published in | Expert Opinion on Drug Metabolism & Toxicology | Q5421205 |
| P1476 | title | The role of fulvestrant in endometrial cancer | |
| P478 | volume | 13 | |